CN113574070B - 用于治疗骨肉瘤的组合物和使用方法 - Google Patents

用于治疗骨肉瘤的组合物和使用方法 Download PDF

Info

Publication number
CN113574070B
CN113574070B CN202080017438.4A CN202080017438A CN113574070B CN 113574070 B CN113574070 B CN 113574070B CN 202080017438 A CN202080017438 A CN 202080017438A CN 113574070 B CN113574070 B CN 113574070B
Authority
CN
China
Prior art keywords
antibody
sequence
seq
aspects
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080017438.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113574070A (zh
Inventor
姜欣
M·里克尔梅
顾肃敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Priority to CN202510142075.1A priority Critical patent/CN119950706A/zh
Publication of CN113574070A publication Critical patent/CN113574070A/zh
Application granted granted Critical
Publication of CN113574070B publication Critical patent/CN113574070B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080017438.4A 2019-02-28 2020-02-28 用于治疗骨肉瘤的组合物和使用方法 Active CN113574070B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510142075.1A CN119950706A (zh) 2019-02-28 2020-02-28 用于治疗骨肉瘤的组合物和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811938P 2019-02-28 2019-02-28
US62/811,938 2019-02-28
PCT/US2020/020343 WO2020176844A1 (en) 2019-02-28 2020-02-28 Compositions for treating osteosarcoma and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510142075.1A Division CN119950706A (zh) 2019-02-28 2020-02-28 用于治疗骨肉瘤的组合物和使用方法

Publications (2)

Publication Number Publication Date
CN113574070A CN113574070A (zh) 2021-10-29
CN113574070B true CN113574070B (zh) 2025-02-25

Family

ID=72238666

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080017438.4A Active CN113574070B (zh) 2019-02-28 2020-02-28 用于治疗骨肉瘤的组合物和使用方法
CN202510142075.1A Pending CN119950706A (zh) 2019-02-28 2020-02-28 用于治疗骨肉瘤的组合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510142075.1A Pending CN119950706A (zh) 2019-02-28 2020-02-28 用于治疗骨肉瘤的组合物和使用方法

Country Status (7)

Country Link
US (1) US20220162298A1 (enExample)
EP (1) EP3931222A4 (enExample)
JP (1) JP7710374B2 (enExample)
CN (2) CN113574070B (enExample)
AU (1) AU2020229374A1 (enExample)
CA (1) CA3131925A1 (enExample)
WO (1) WO2020176844A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277928A4 (en) * 2021-01-13 2025-03-19 Board of Regents, The University of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS AND JOINT AND TENDON DISEASES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091903A1 (en) * 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
JP2022522011A (ja) 2022-04-13
AU2020229374A2 (en) 2021-10-21
EP3931222A1 (en) 2022-01-05
WO2020176844A1 (en) 2020-09-03
JP7710374B2 (ja) 2025-07-18
EP3931222A4 (en) 2023-11-01
AU2020229374A1 (en) 2021-08-19
CN113574070A (zh) 2021-10-29
CN119950706A (zh) 2025-05-09
CA3131925A1 (en) 2020-09-03
US20220162298A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US12503500B2 (en) Connexin 43 (Cx43) hemichannel-binding antibodies
JP4679035B2 (ja) 併用療法
CN113260385B (zh) 抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
KR20170058960A (ko) Agr2 및 그의 수용체 c4.4a 에 대한 차단 모노클로날 항체
IL310865A (en) Antibodies against EDB and antibody-drug conjugates
JP7710374B2 (ja) 骨肉腫を治療するための組成物及び使用方法
US10759857B2 (en) JAM-C antibodies and methods for treatment of cancer
HK40062936A (en) Compositions for treating osteosarcoma and methods of use
HK40062936B (en) Compositions for treating osteosarcoma and methods of use
KR20220143904A (ko) 사람 4-1bb 항진제 항체 및 이의 사용 방법
HK40100475A (en) Connexin (cx)43 hemichannel-binding antibodies and uses thereof
HK1262261B (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
HK1262261A1 (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
CN117377686A (zh) 用于治疗骨关节炎、类风湿性关节炎以及关节和肌腱病症的组合物和方法
HK1244816A1 (en) Blocking monoclonal antibodies to agr2 and its receptor c4.4a

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062936

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant